Trial Profile
A Prospective Randomized, Open-label Phase 2 Study of Immune Checkpoint Inhibition, Nivolumab With or Without Ipilimumab in Combination With Radiation Therapy in Pretreated Patients With Metastatic Pancreatic Cancer or Biliary Tract Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CheckPAC
- 21 Jan 2023 Results (n=61) assessing efficacy and toxicity in cholangiocarcinoma and gallbladder cancer cohorts presented at the 2023 Gastrointestinal Cancers Symposium
- 17 Nov 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 Results evaluating the clinical benefit of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy, published in the Journal of Clinical Oncology